<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" bill-type="olc" public-print="no" public-private="public" stage-count="1" star-print="no-star-print">
	<form display="yes">
		<distribution-code display="yes">II</distribution-code>
		<congress display="yes">110th CONGRESS</congress>
		<session display="yes">1st Session</session>
		<legis-num display="yes">S. 438</legis-num>
		<current-chamber display="yes">IN THE SENATE OF THE UNITED
		  STATES</current-chamber>
		<action display="yes">
			<action-date date="20070130">January 30, 2007</action-date>
			<action-desc><sponsor name-id="S176">Mr. Rockefeller</sponsor> (for
			 himself, <cosponsor name-id="S270">Mr. Schumer</cosponsor>,
			 <cosponsor name-id="S209">Mr. Kohl</cosponsor>, and <cosponsor name-id="S057">Mr. Leahy</cosponsor>) introduced the following bill; which was
			 read twice and referred to the <committee-name committee-id="SSHR00">Committee
			 on Health, Education, Labor, and Pensions</committee-name></action-desc>
		</action>
		<legis-type display="yes">A BILL</legis-type>
		<official-title display="yes">To amend the Federal Food, Drug, and
		  Cosmetic Act to prohibit the marketing of authorized generic
		  drugs.</official-title>
	</form>
	<legis-body display-enacting-clause="yes-display-enacting-clause" style="OLC">
		<section commented="no" display-inline="no-display-inline" id="idEE2D477AE7814717ADF99C528F6B6967" section-type="section-one"><enum>1.</enum><header display-inline="yes-display-inline">Short title</header><text display-inline="no-display-inline">This Act may be cited as the
			 <quote><short-title>Fair Prescription Drug Competition
			 Act</short-title></quote>.</text>
		</section><section commented="no" display-inline="no-display-inline" id="idF27502154AC84B6DA68803A5540C7960" section-type="subsequent-section"><enum>2.</enum><header display-inline="yes-display-inline">Prohibition of authorized
			 generics</header><text display-inline="no-display-inline">Section 505 of the
			 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) is amended by adding at
			 the end the following:</text>
			<quoted-block display-inline="no-display-inline" id="idFB59A2191D344C0EBD11F90EA8C08D21" style="OLC">
				<subsection commented="no" display-inline="no-display-inline" id="idF113701517434824BC0BDBD371FB5507"><enum>(o)</enum><header display-inline="yes-display-inline">Prohibition of authorized generic
				drugs</header>
					<paragraph commented="no" display-inline="no-display-inline" id="idEE15805DFE794636B89B6BBD9737E6E2"><enum>(1)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">Notwithstanding any other provision of this
				Act, no holder of a new drug application approved under subsection (c) shall
				manufacture, market, sell, or distribute an authorized generic drug, direct or
				indirectly, or authorize any other person to manufacture, market, sell, or
				distribute an authorized generic drug.</text>
					</paragraph><paragraph commented="no" display-inline="no-display-inline" id="idB1E8852B4D9F4064B1E1D09C5A7C2547"><enum>(2)</enum><header display-inline="yes-display-inline">Authorized generic drug</header><text display-inline="yes-display-inline">For purposes of this subsection, the term
				<term>authorized generic drug</term>—</text>
						<subparagraph commented="no" display-inline="no-display-inline" id="id1C6F26E56A604092B31C54F646E818EC"><enum>(A)</enum><text display-inline="yes-display-inline">means any version of a listed drug (as such
				term is used in subsection (j)) that the holder of the new drug application
				approved under subsection (c) for that listed drug seeks to commence marketing,
				selling, or distributing, directly or indirectly, after receipt of a notice
				sent pursuant to subsection (j)(2)(B) with respect to that listed drug;
				and</text>
						</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id729A5F060ADF4E58B66F4EE61ECFE2E4"><enum>(B)</enum><text display-inline="yes-display-inline">does not include any drug to be marketed,
				sold, or distributed—</text>
							<clause commented="no" display-inline="no-display-inline" id="idD2CEBDE67273413B8DA9740C4676E80B"><enum>(i)</enum><text display-inline="yes-display-inline">by an entity eligible for exclusivity with
				respect to such drug under subsection (j)(5)(B)(iv); or</text>
							</clause><clause commented="no" display-inline="no-display-inline" id="id21D68AAF22C04B6197B3605F4A9FF610"><enum>(ii)</enum><text display-inline="yes-display-inline">after expiration or forfeiture of any
				exclusivity with respect to such drug under such subsection
				(j)(5)(B)(iv).</text>
							</clause></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
		</section></legis-body>
</bill>
